Tagomics Ltd., a precision medicine company, has launched LiquiPath™, a cross-species, multi-organ liquid pathology platform designed for non-invasive drug safety monitoring. The platform is intended for use across preclinical research, clinical development and post-market surveillance. Tagomics has also opened an early access programme for the technology.

Drug-induced toxicity remains a major challenge in drug developent and patient care. It can contribute to clinical trial failures, development delays, treatment interruptions and potentially permanent organ damage. Current safety monitoring methods often rely on non-specific biomarkers, imaging and clinical symptoms, which may detect injury only after substantial damage has occurred.

LiquiPath combines Tagomics’ epigenetic technology, Activace, with propmrietary cell-specific methylation atlases and deconvolution algorithms. The platform analyses circulating cell-free DNA (cfDNA) in blood and traces it back to its tissue of origin. This approach is designed to identify treatment-related effects across multiple organs from a single blood sample.

In preclinical studies, LiquiPath’s multi-species and multi-organ capabilities could reduce reliance on histopathology and animal testing while supporting faster toxicity assessment and risk classification.

In clinical development, the platform is designed to detect early signs of subclinical toxicity, support adverse event prediction and improve patient stratification. Earlier identification of potential organ damage could help drug developers make better-informed decisions and support safer, longer-term treatment.

Tagomics is developing LiquiPath through projects with pharmaceutical companies, including AstraZeneca, across different therapeutic areas and stages of drug development. The company is inviting additional pharmaceutical partners to join its early access programme and work on priority applications, validation studies and future platform development.

The launch also expands Tagomics’ focus beyond cancer detection and supports its broader strategy to apply precision medicine technologies to drug safety monitoring.

 

Source: tagomics.com

Report Abuse